640 articles
Protamine sulfate
Protamine sulfate, a basic polypeptide from salmon sperm (now recombinant), is the only approved agent reversing unfractionated heparin, dosed 1-1.5 mg per 100 units heparin, mainly after cardiopulmonary bypass.
Puberty suppression
Puberty suppression is a medical treatment that delays the physical changes of puberty with GnRH agonists, given to adolescents with gender dysphoria or precocious puberty.
Qizhi Yishen capsules
Qizhi Yishen capsules (芪蛭益肾胶囊), a Class 1.1 innovative Chinese medicine by Shandong Phoenix Pharmaceutical approved November 2021 for early diabetic kidney disease with qi-yin deficiency pattern; first such TCM drug, reimbursed nationally since 2023.
Quinagolide
Quinagolide (CV 205-502, Norprolac) is a non-ergot selective dopamine D2 receptor agonist taken once daily for hyperprolactinemia and prolactinoma, mainly in Europe; UK tablets discontinued in 2026.
Quinestrol
Quinestrol is a long-acting synthetic estrogen, the 3-cyclopentyl ether of ethinyl estradiol, formerly marketed as Estrovis and now used mainly in rodent fertility control research.
Quinethazone
Quinethazone (Hydromox) is a quinazoline-derived thiazide-like diuretic and antihypertensive, FDA-approved April 10, 1963 (NDA 013264, Lederle, 50 mg tablet), acting via distal tubule Na-Cl cotransporter inhibition; now discontinued.
Quinidine
Quinidine, D-isomer of quinine from cinchona bark, is a class IA antiarrhythmic (sodium and potassium channel blocker) once standard for atrial fibrillation, now limited by proarrhythmia and mortality signals but used in Brugada syndrome and idiopathic ventricular fibrillation.
Rafutrombopag
Rafutrombopag, the INN for hetrombopag (SHR8735), is Jiangsu Hengrui's oral nonpeptide thrombopoietin receptor agonist approved in China for ITP and severe aplastic anemia, with US orphan designation for chemotherapy-induced thrombocytopenia.
Ragaglitazar
Ragaglitazar, (−) DRF 2725, NNC 61-0029, a dual PPARα/γ agonist for type 2 diabetes from Dr. Reddy's and Novo Nordisk; effective on glucose and lipids but discontinued in 2003 over rat urothelial tumors.
Ralinepag
Ralinepag (APD811) is an oral, highly selective non-prostanoid prostacyclin (IP) receptor agonist developed by United Therapeutics for pulmonary arterial hypertension; once-daily extended-release tablet, positive phase 3 ADVANCE OUTCOMES, FDA NDA under review, not yet approved.
Ramipril
Ramipril (Altace, Tritace) is an ACE inhibitor prodrug converted to ramiprilat, used for hypertension, post-MI heart failure, and cardiovascular risk reduction; HOPE trial showed 22% relative risk reduction in MI, stroke, or cardiovascular death.
Ramulus Mori (mulberry twig) total alkaloids tablets
Ramulus Mori (mulberry twig) total alkaloids tablets (桑枝总生物碱片, Sangbo'en), China's first original natural glucose-lowering drug, approved 17 March 2020 for type 2 diabetes; α-glucosidase inhibitor from mulberry twigs, non-inferior to acarbose with fewer GI reactions.
Ranirestat
Ranirestat (AS-3201) is an oral aldose reductase inhibitor developed by Sumitomo Pharma and Kyorin for diabetic neuropathy; it reached phase 3 trials, improved nerve conduction velocity but not symptom scores, and development was discontinued in 2016.
Ranolazine
Ranolazine (Ranexa), an antianginal drug approved in the US (2006) and EU (2008) for chronic/stable angina; inhibits the late sodium current, reducing calcium overload without changing heart rate or blood pressure; null outcome trials, QT prolongation, CYP3A interactions.
RAY1225
RAY1225 is an investigational biweekly GLP-1/GIP dual receptor agonist injection by Guangdong Raynovent Biotech (Zhongsheng Pharma), in phase 3 for obesity and type 2 diabetes, with phase 2 weight loss up to 21.18% at 24 weeks.
RBD5044
RBD5044: GalNAc-conjugated siRNA by Suzhou Ribo Life Science targeting ApoC3 for hypertriglyceridemia; second ApoC3 siRNA in clinic; phase 1 cut ApoC3 up to 84% and triglycerides up to 70%; phase 2 trials in Sweden and China.
RBD7022 (QLC7401)
RBD7022, known as QLC7401 in Greater China, is a GalNAc-conjugated siRNA targeting PCSK9 mRNA to lower LDL cholesterol, developed by Suzhou Ribo Life Science and licensed to Qilu Pharmaceutical.
RBx-10558
RBx-10558 (PPD-10558) was a Ranbaxy-discovered HMG-CoA reductase inhibitor statin for dyslipidemia, licensed to PPD/Furiex in 2007; its Phase 2b trial in statin-associated myalgia (NCT01279590, 282 patients) missed its endpoint and development stopped in 2011.
Recombinant human prourokinase
Recombinant human prourokinase (rhPro-UK, 普佑克/Puyouke) is a CHO-cell-expressed fibrinolytic drug by Tasly, approved in China in 2011 for STEMI thrombolysis and the only marketed recombinant prourokinase product in China, with stroke and pulmonary embolism trials.
Recombinant human thyroid-stimulating hormone (Zelgen)
Recombinant human thyroid-stimulating hormone (rhTSH) is an injectable drug that raises TSH in thyroid cancer patients so radioiodine scans and thyroglobulin testing work without stopping thyroid hormone pills.
Regadenoson anhydrous
Regadenoson anhydrous (Lexiscan, Rapiscan) is a selective A2A adenosine receptor agonist coronary vasodilator given as a fixed 0.4 mg IV bolus for myocardial perfusion imaging stress testing.
Reloxaliase
Reloxaliase (ALLN-177) is an oral recombinant oxalate decarboxylase enzyme developed by Allena Pharmaceuticals to treat enteric hyperoxaluria; URIROX-1 showed reduced urinary oxalate, but the phase 3 URIROX-2 trial was terminated.
Rescinnamine
Rescinnamine (Moderil) is a Rauwolfia serpentina indole alkaloid antihypertensive, C35H42N2O9, ATC C02AA01, described as an ACE inhibitor by DrugBank; FDA approved 1956, later discontinued.
Reserpine
Reserpine, an alkaloid of Rauwolfia serpentina isolated at Ciba in 1952 (brand Serpasil), was the first widely used long-term antihypertensive and an early antipsychotic; it lowers systolic pressure about 8 mmHg but is now withdrawn in the US.
Retagliptin and metformin tablets
Retagliptin and metformin tablets (瑞格列汀二甲双胍片, Ruilintang) is a Hengrui Category 1 fixed-dose combination of the DPP-4 inhibitor retagliptin 50 mg and metformin 850 mg, approved in China in May 2025 for type 2 diabetes adults.
Retagliptin phosphate
Retagliptin phosphate (瑞泽唐) is a DPP-4 inhibitor by Jiangsu Hengrui, approved by China's NMPA in June 2023 as a Category 1 drug for adult type 2 diabetes; China's first domestically developed gliptin.
Retagliptin, henagliflozin, and metformin tablets
Henagliflozin/retagliptin/metformin extended-release tablets (恒格列净瑞格列汀二甲双胍缓释片), a Hengrui once-daily triple fixed-dose combination for type 2 diabetes, NMPA-approved 21 October 2025; phase 3 showed HbA1c reductions of 1.51–1.54% at 24 weeks.
Reteplase
Reteplase (r-PA, Rapilysin) is a nonglycosylated recombinant tPA deletion mutant thrombolytic with kringle-2 and protease domains, given as two 10-unit boluses 30 minutes apart; FDA-approved 1996 for myocardial infarction, EU authorization withdrawn 2024.
Retosiban
Retosiban (GSK221149A) is a non-peptide, orally bioavailable oxytocin receptor antagonist developed by GSK as a tocolytic for spontaneous preterm labor; Phase 3 ended with recruitment failure and the program was terminated.
RGT-075 (oral GLP-1R agonist)
RGT-075 (RGT001-075) is Regor Therapeutics' oral, once-daily small-molecule full agonist of the GLP-1 receptor, discovered via its CARD platform, in phase 2b/3 trials for obesity and type 2 diabetes after 5% placebo-adjusted weight loss in phase 2a.